A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

Alfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Francis Giles, Deborah Thomas, William Wierda, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30-50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2-89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2-20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.

Original languageEnglish (US)
Pages (from-to)283-289
Number of pages7
JournalLeukemia and Lymphoma
Volume48
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Idarubicin
Blast Crisis
Cytarabine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem Cell Transplantation
Proxy
Cytogenetics
Outpatients
Survival
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Garcia-Manero, Guillermo; O'Brien, Susan; Faderl, Stefan; Ravandi, Farhad; Giles, Francis; Thomas, Deborah; Wierda, William; Cortes, Jorge.

In: Leukemia and Lymphoma, Vol. 48, No. 2, 01.02.2007, p. 283-289.

Research output: Contribution to journalReview article

Quintás-Cardama, A, Kantarjian, H, Garcia-Manero, G, O'Brien, S, Faderl, S, Ravandi, F, Giles, F, Thomas, D, Wierda, W & Cortes, J 2007, 'A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase', Leukemia and Lymphoma, vol. 48, no. 2, pp. 283-289. https://doi.org/10.1080/10428190601075973
Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; Garcia-Manero, Guillermo ; O'Brien, Susan ; Faderl, Stefan ; Ravandi, Farhad ; Giles, Francis ; Thomas, Deborah ; Wierda, William ; Cortes, Jorge. / A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 2. pp. 283-289.
@article{2c1f5ff481af42f09756dfd9bd6e2ae2,
title = "A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase",
abstract = "Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30-50{\%} of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74{\%}) achieved a hematologic response: CHR in 9 (47{\%}) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26{\%}). Median duration of response was 10 weeks (range, 2-89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2-20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Guillermo Garcia-Manero and Susan O'Brien and Stefan Faderl and Farhad Ravandi and Francis Giles and Deborah Thomas and William Wierda and Jorge Cortes",
year = "2007",
month = "2",
day = "1",
doi = "10.1080/10428190601075973",
language = "English (US)",
volume = "48",
pages = "283--289",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Giles, Francis

AU - Thomas, Deborah

AU - Wierda, William

AU - Cortes, Jorge

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30-50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2-89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2-20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.

AB - Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30-50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2-89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2-20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.

UR - http://www.scopus.com/inward/record.url?scp=34247853362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247853362&partnerID=8YFLogxK

U2 - 10.1080/10428190601075973

DO - 10.1080/10428190601075973

M3 - Review article

C2 - 17325887

AN - SCOPUS:34247853362

VL - 48

SP - 283

EP - 289

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -